Literature DB >> 22721793

Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice.

Juan A Virizuela1, Yolanda Escobar, Javier Cassinello, Pablo Borrega.   

Abstract

Cancer pain should be controlled in most patients, however this is not always achieved. These guidelines describe the classification, evaluation and treatment of chronic cancer pain in accordance with the WHO treatment strategy of pain stages: mild, moderate and severe. For treatment during the third stage, we cover titration and rotation of opioids, as well as their side effects and prevention. Also described is neuropathic pain and refractory pain, coadjuvant treatments and non pharmacological analgesic treatments. Finally, treatment of breakthrough pain is defined.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721793     DOI: 10.1007/s12094-012-0831-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  20 in total

Review 1.  The pharmacologic management of cancer pain.

Authors:  Nathan I Cherny
Journal:  Oncology (Williston Park)       Date:  2004-10       Impact factor: 2.990

Review 2.  The role of opioids in cancer pain.

Authors:  Columba Quigley
Journal:  BMJ       Date:  2005-10-08

Review 3.  Principles of control of cancer pain.

Authors:  Marie Fallon; Geoffrey Hanks; Nathan Cherny
Journal:  BMJ       Date:  2006-04-29

4.  A validation study of the WHO analgesic ladder: a two-step vs three-step strategy.

Authors:  Marco Maltoni; Emanuela Scarpi; Caterina Modonesi; Alessandro Passardi; Sebastiano Calpona; Adriana Turriziani; Raffaella Speranza; Davide Tassinari; Pierantonio Magnani; Denis Saccani; Luigi Montanari; Britt Roudnas; Dino Amadori; Laura Fabbri; Oriana Nanni; Paola Raulli; Barbara Poggi; Francesca Fochessati; Donatella Giannunzio; Maria Lucia Barbagallo; Vincenzo Minnotti; Maura Betti; Stefano Giordani; Elena Piazza; Roberto Scapaticci; Sabrina Ferrario
Journal:  Support Care Cancer       Date:  2005-04-08       Impact factor: 3.603

5.  Low morphine doses in opioid-naive cancer patients with pain.

Authors:  Sebastiano Mercadante; Gianpiero Porzio; Patrizia Ferrera; Fabio Fulfaro; Federica Aielli; Corrado Ficorella; Lucilla Verna; Walter Tirelli; Patrizia Villari; Edoardo Arcuri
Journal:  J Pain Symptom Manage       Date:  2006-03       Impact factor: 3.612

Review 6.  Sedation for the care of patients with advanced cancer.

Authors:  Nathan I Cherny
Journal:  Nat Clin Pract Oncol       Date:  2006-09

7.  Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group.

Authors:  Maria Teresa Greco; Oscar Corli; Mauro Montanari; Silvia Deandrea; Vittorina Zagonel; Giovanni Apolone
Journal:  Clin J Pain       Date:  2011-01       Impact factor: 3.442

8.  Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial.

Authors:  Martin Stockler; Janette Vardy; Avinesh Pillai; David Warr
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 9.  Intraspinal techniques for pain management in cancer patients: a systematic review.

Authors:  Jeff Myers; Vincent Chan; Virginia Jarvis; Cindy Walker-Dilks
Journal:  Support Care Cancer       Date:  2010-02       Impact factor: 3.603

Review 10.  Bisphosphonates for the relief of pain secondary to bone metastases.

Authors:  R Wong; P J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2002
View more
  10 in total

1.  SEOM clinical guidelines: a consolidated project.

Authors:  Juan J Cruz Hernández; César A Rodríguez
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

2.  Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).

Authors:  J Porta-Sales; C Pérez; Y Escobar; V Martínez
Journal:  Clin Transl Oncol       Date:  2015-12-22       Impact factor: 3.405

3.  Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.

Authors:  R López López; C Camps Herrero; P Khosravi-Shahi; V Guillem Porta; A Carrato Mena; J Garcia-Foncillas; J J Cruz Hernández; P Gascón Vilaplana; A Antón Torres; E Diaz-Rubio; M Feyjoo Saus; E Aranda Aguilar
Journal:  Clin Transl Oncol       Date:  2017-10-03       Impact factor: 3.405

Review 4.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

5.  Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study.

Authors:  J Boceta; A De la Torre; D Samper; M Farto; R Sánchez-de la Rosa
Journal:  Clin Transl Oncol       Date:  2016-11       Impact factor: 3.405

6.  SEOM clinical guideline for treatment of cancer pain (2017).

Authors:  C Jara; S Del Barco; C Grávalos; S Hoyos; B Hernández; M Muñoz; T Quintanar; J A Meana; C Rodriguez; R de Las Peñas
Journal:  Clin Transl Oncol       Date:  2017-11-10       Impact factor: 3.405

7.  Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.

Authors:  Carlos Camps Herrero; Antonio Antón Torres; Juan Jesús Cruz-Hernández; Alfredo Carrato; Manuel Constenla; Eduardo Díaz-Rubio; Margarita Feyjoo Saus; Jesus Garcia-Foncillas; Pere Gascón; Vicente Guillem
Journal:  J Pain Res       Date:  2019-07-29       Impact factor: 3.133

8.  [Observational and cross-sectional study of prevalence and severity of the opioid-induced bowel dysfunction].

Authors:  Rafael Gálvez; Mariano Provencio; Manuel Cobo; Cristina Pérez; Concha Pérez; Jaume Canal
Journal:  Aten Primaria       Date:  2013-12-13       Impact factor: 1.137

9.  Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.

Authors:  Masoud Hashemi; Alireza Zali; Ebrahim Golmakani; Mohammad Hossein Delshad; Mahdi Shadnoush; Mohammad-Esmaeil Akbari
Journal:  Daru       Date:  2021-01-21       Impact factor: 3.117

10.  Breakthrough cancer pain - still a challenge.

Authors:  Cesar Margarit; Joaquim Juliá; Rafael López; Antonio Anton; Yolanda Escobar; Ana Casas; Juan Jesús Cruz; Rafael Galvez; Ana Mañas; Francisco Zaragozá
Journal:  J Pain Res       Date:  2012-11-19       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.